🔶 Definium Therapeutics at the 2026 RBC Capital Markets Global Healthcare Conference 🔶

Definium Therapeutics describes the status of its clinical trials for a specialized LSD formulation, emphasizing their focus on Major Depressive Disorder (MDD) and Generalized Anxiety Disorder (GAD). The company highlights key findings such as dose response and patient retention rates, as well as the implementation of open-label extension studies to reduce dropout rates. The interview outlines their multi-layered intellectual property strategy, which includes patents for specific formulations and potential drug delivery methods. Additionally, the company discusses the importance of building commercial relationships with clinical centers, and managing market presence as a way of preparing for future product launch. The conversation emphasizes the company's objective to demonstrate durable efficacy across their target indications. They mention that while GAD studies show positive results, they seek to further validate their treatments and streamline FDA communication to accelerate bringing these therapies to patients. Definium Therapeutics focuses on creating reliable and scalable treatment models for patients with anxiety and depression, while engaging with payers to discuss reimbursement frameworks and the value proposition of their psychedelic-assisted therapeutic approaches.